FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4240236213> ?p ?o ?g. }

• W4240236213 abstract "Background Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction to colonisation of the lungs with the fungus Aspergillus fumigatus and affects around 10% of people with cystic fibrosis. ABPA is associated with an accelerated decline in lung function. High doses of corticosteroids are the main treatment for ABPA; although the long‐term benefits are not clear, their many side effects are well‐documented. A group of compounds, the azoles, have activity against Aspergillus fumigatus and have been proposed as an alternative treatment for ABPA. Of this group, itraconazole is the most active. A separate antifungal compound, amphotericin B, has been employed in aerosolised form to treat invasive infection with Aspergillus fumigatus, and may have potential for the treatment of ABPA. Antifungal therapy for ABPA in cystic fibrosis needs to be evaluated. Objectives The review aimed to test the hypotheses that antifungal interventions for the treatment of ABPA in cystic fibrosis: 1. improve clinical status compared to placebo or standard therapy (no placebo); 2. do not have unacceptable adverse effects. If benefit was demonstrated, we aimed to assess the optimal type, duration and dose of antifungal therapy. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. In addition, pharmaceutical companies were approached. Date of the most recent search of the Group's Trials Register: 17 March 2014. Selection criteria Published or unpublished randomised controlled trials, where antifungal treatments have been compared to either placebo or no treatment, or where different doses of the same treatment have been used in the treatment of ABPA in people with cystic fibrosis. Data collection and analysis Four trials were identified by the searches; none of which was judged eligible for inclusion in the review. Main results No completed randomised controlled trials were included. Authors' conclusions At present, there are no randomised controlled trials to evaluate the use of antifungal therapies for the treatment of ABPA in people with cystic fibrosis, although trials in people who do not have cystic fibrosis have shown clinical and serological evidence of improvement and a reduction in the use of corticosteroids with no increase in adverse effects. Trials with clear outcome measures are needed to properly evaluate this potentially useful treatment for cystic fibrosis." @default.
• W4240236213 created "2022-05-12" @default.
• W4240236213 creator A5024306774 @default.
• W4240236213 creator A5049835765 @default.
• W4240236213 date "2014-11-28" @default.
• W4240236213 modified "2023-09-28" @default.
• W4240236213 title "Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis" @default.
• W4240236213 cites W1946256898 @default.
• W4240236213 cites W1974893215 @default.
• W4240236213 cites W1988195179 @default.
• W4240236213 cites W1990490872 @default.
• W4240236213 cites W1997775131 @default.
• W4240236213 cites W1997855218 @default.
• W4240236213 cites W1998979526 @default.
• W4240236213 cites W2005581514 @default.
• W4240236213 cites W2005894108 @default.
• W4240236213 cites W2075425014 @default.
• W4240236213 cites W2077424676 @default.
• W4240236213 cites W2082792877 @default.
• W4240236213 cites W2120902620 @default.
• W4240236213 cites W2122670779 @default.
• W4240236213 cites W2135649656 @default.
• W4240236213 cites W2136496779 @default.
• W4240236213 cites W2150817537 @default.
• W4240236213 cites W2153044469 @default.
• W4240236213 cites W4241558184 @default.
• W4240236213 cites W4245632000 @default.
• W4240236213 cites W92943117 @default.
• W4240236213 doi "https://doi.org/10.1002/14651858.cd002204.pub3" @default.
• W4240236213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25431975" @default.
• W4240236213 hasPublicationYear "2014" @default.
• W4240236213 type Work @default.
• W4240236213 citedByCount "11" @default.
• W4240236213 countsByYear W42402362132015 @default.
• W4240236213 countsByYear W42402362132016 @default.
• W4240236213 countsByYear W42402362132017 @default.
• W4240236213 countsByYear W42402362132018 @default.
• W4240236213 countsByYear W42402362132019 @default.
• W4240236213 countsByYear W42402362132021 @default.
• W4240236213 countsByYear W42402362132022 @default.
• W4240236213 crossrefType "reference-entry" @default.
• W4240236213 hasAuthorship W4240236213A5024306774 @default.
• W4240236213 hasAuthorship W4240236213A5049835765 @default.
• W4240236213 hasBestOaLocation W42402362131 @default.
• W4240236213 hasConcept C126322002 @default.
• W4240236213 hasConcept C141105273 @default.
• W4240236213 hasConcept C142724271 @default.
• W4240236213 hasConcept C159654299 @default.
• W4240236213 hasConcept C16005928 @default.
• W4240236213 hasConcept C177713679 @default.
• W4240236213 hasConcept C197934379 @default.
• W4240236213 hasConcept C203014093 @default.
• W4240236213 hasConcept C204787440 @default.
• W4240236213 hasConcept C27081682 @default.
• W4240236213 hasConcept C2776391196 @default.
• W4240236213 hasConcept C2776938444 @default.
• W4240236213 hasConcept C2777071850 @default.
• W4240236213 hasConcept C2778871687 @default.
• W4240236213 hasConcept C2779548794 @default.
• W4240236213 hasConcept C2779629538 @default.
• W4240236213 hasConcept C2779787849 @default.
• W4240236213 hasConcept C2780690907 @default.
• W4240236213 hasConcept C71924100 @default.
• W4240236213 hasConceptScore W4240236213C126322002 @default.
• W4240236213 hasConceptScore W4240236213C141105273 @default.
• W4240236213 hasConceptScore W4240236213C142724271 @default.
• W4240236213 hasConceptScore W4240236213C159654299 @default.
• W4240236213 hasConceptScore W4240236213C16005928 @default.
• W4240236213 hasConceptScore W4240236213C177713679 @default.
• W4240236213 hasConceptScore W4240236213C197934379 @default.
• W4240236213 hasConceptScore W4240236213C203014093 @default.
• W4240236213 hasConceptScore W4240236213C204787440 @default.
• W4240236213 hasConceptScore W4240236213C27081682 @default.
• W4240236213 hasConceptScore W4240236213C2776391196 @default.
• W4240236213 hasConceptScore W4240236213C2776938444 @default.
• W4240236213 hasConceptScore W4240236213C2777071850 @default.
• W4240236213 hasConceptScore W4240236213C2778871687 @default.
• W4240236213 hasConceptScore W4240236213C2779548794 @default.
• W4240236213 hasConceptScore W4240236213C2779629538 @default.
• W4240236213 hasConceptScore W4240236213C2779787849 @default.
• W4240236213 hasConceptScore W4240236213C2780690907 @default.
• W4240236213 hasConceptScore W4240236213C71924100 @default.
• W4240236213 hasLocation W42402362131 @default.
• W4240236213 hasLocation W42402362132 @default.
• W4240236213 hasOpenAccess W4240236213 @default.
• W4240236213 hasPrimaryLocation W42402362131 @default.
• W4240236213 hasRelatedWork W1969061991 @default.
• W4240236213 hasRelatedWork W2102326747 @default.
• W4240236213 hasRelatedWork W2115522792 @default.
• W4240236213 hasRelatedWork W2123852339 @default.
• W4240236213 hasRelatedWork W2156860818 @default.
• W4240236213 hasRelatedWork W2157887645 @default.
• W4240236213 hasRelatedWork W2169858659 @default.
• W4240236213 hasRelatedWork W2374889891 @default.
• W4240236213 hasRelatedWork W4318263015 @default.
• W4240236213 hasRelatedWork W3149065072 @default.
• W4240236213 isParatext "false" @default.
• W4240236213 isRetracted "false" @default.
• W4240236213 workType "reference-entry" @default.